Could tailored tamoxifen doses keep more breast cancer patients on treatment?
NCT ID NCT07502820
First seen Apr 04, 2026 · Last updated Jun 11, 2026 · Updated 14 times
Summary
This phase 3 trial tests whether adjusting tamoxifen doses based on individual metabolism can reduce the number of breast cancer patients who stop treatment early due to side effects. About 1,100 premenopausal or perimenopausal women with hormone-sensitive breast cancer will receive either standard or personalized dosing. The goal is to improve adherence and survival outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Capio S:t Görans Sjukhus
Stockholm, 112 81, Sweden
Contact
-
S:a Älvsborgs Sjukhus
Borås, 501 82, Sweden
Contact
-
Skaraborgs Sjukhus
Skövde, 549 49, Sweden
Contact
-
Södersjukhuset, Onkologiska kliniken
Stockholm, 118 61, Sweden
Contact
Conditions
Explore the condition pages connected to this study.